Camellia. API's fortunes could be turning

The fortunes of Australia Pharmaceutical Industries (API), at Camellia, could be turning, compared with its competitor, Sigma Pharmaceutical, after API’s first-half result convinced several brokers the worst may be over for the drug distributor, according to The Australian Financial Review. APO posted flat revenue and underlying net profit that excludes one-off costs of $1.85 billion and $11.2 million respectively.